Gianluca Gaidano Selected Research

fludarabine

11/2023	Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.
1/2023	Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
1/2020	HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.
11/2018	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
1/2018	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
2/2016	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
10/2015	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
4/2015	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
10/2014	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
4/2014	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gianluca Gaidano Research Topics

Disease

81	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 09/2023 - 05/2002
68	Neoplasms (Cancer) 03/2024 - 01/2002
31	Lymphoma (Lymphomas) 09/2023 - 07/2002
29	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2023 - 01/2002
17	Multiple Myeloma 01/2022 - 05/2002
15	Disease Progression 08/2023 - 08/2003
13	COVID-19 01/2024 - 07/2020
11	B-Cell Lymphoma (Lymphoma, B Cell) 12/2021 - 01/2003
11	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 09/2014 - 11/2003
9	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 02/2012
9	Infections 11/2023 - 08/2003
9	Leukemia 12/2022 - 10/2011
9	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 07/2022 - 02/2012
7	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 03/2011
6	Residual Neoplasm 12/2021 - 09/2014
6	Hemorrhage 01/2021 - 06/2004
6	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2020 - 02/2006
5	Neutropenia 01/2021 - 09/2015
5	Thrombocytopenia (Thrombopenia) 12/2018 - 06/2014
5	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2015 - 12/2002
4	Fatigue 01/2023 - 02/2015
4	Acquired Immunodeficiency Syndrome (AIDS) 03/2007 - 01/2002
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2021 - 01/2016
3	Hypoxia (Hypoxemia) 01/2020 - 11/2016
3	Waldenstrom Macroglobulinemia (Macroglobulinemia) 10/2018 - 11/2013
3	Pneumonia (Pneumonitis) 04/2016 - 09/2015
3	Burkitt Lymphoma (Burkitt's Lymphoma) 12/2004 - 01/2002
2	Stomatitis 11/2023 - 09/2015
2	Atrial Fibrillation 09/2022 - 10/2018
2	Diarrhea 09/2022 - 12/2015
2	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 08/2012
2	Hairy Cell Leukemia 01/2021 - 05/2008
2	Injection Site Reaction 01/2019 - 11/2015
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2019 - 10/2015

Drug/Important Bio-Agent (IBA)

36	Rituximab (Mabthera)FDA Link 11/2023 - 12/2002
19	ibrutinibIBA 01/2023 - 03/2014
19	DNA (Deoxyribonucleic Acid)IBA 06/2022 - 01/2002
17	Immunoglobulins (Immunoglobulin)IBA 11/2023 - 05/2002
16	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2023 - 01/2002
12	fludarabineIBA 11/2023 - 12/2011
11	Lenalidomide (CC 5013)FDA Link 08/2023 - 11/2013
10	Biomarkers (Surrogate Marker)IBA 06/2023 - 01/2012
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2002
9	Prednisone (Sone)FDA LinkGeneric 01/2018 - 01/2003
8	Bendamustine Hydrochloride FDA Link 01/2021 - 07/2012
8	AntigensIBA 01/2019 - 12/2006
8	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 01/2003
8	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2018 - 05/2002
7	LigandsIBA 03/2024 - 02/2003
7	Monoclonal AntibodiesIBA 12/2023 - 12/2002
7	Vincristine (Oncovin)FDA LinkGeneric 01/2018 - 01/2003
6	Azacitidine (5 Azacytidine)FDA Link 07/2023 - 02/2012
6	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 01/2016
5	Circulating Tumor DNAIBA 06/2022 - 01/2018
5	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020 - 09/2004
5	Bortezomib (Velcade)FDA Link 10/2017 - 12/2010
4	tafasitamabIBA 08/2023 - 01/2020
4	VaccinesIBA 01/2023 - 01/2019
4	Cell-Free Nucleic AcidsIBA 06/2022 - 01/2017
4	Phosphotransferases (Kinase)IBA 01/2021 - 04/2015
4	carfilzomibIBA 01/2021 - 01/2016
4	Chlorambucil (Leukeran)FDA Link 01/2020 - 12/2015
4	Melphalan (Alkeran)FDA LinkGeneric 01/2017 - 07/2010
3	Decitabine FDA Link 05/2024 - 04/2016
3	Agammaglobulinaemia Tyrosine KinaseIBA 03/2024 - 12/2014
3	Oxygen (Dioxygen)IBA 01/2024 - 01/2022
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 01/2003
3	Factor VIII (Coagulation Factor VIII)IBA 01/2022 - 06/2004
3	idelalisibIBA 08/2021 - 01/2019
3	obinutuzumabIBA 01/2020 - 10/2015
3	Tyrosine Kinase InhibitorsIBA 01/2019 - 09/2011
3	MicroRNAs (MicroRNA)IBA 01/2019 - 05/2011
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2018 - 06/2010
3	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2018 - 04/2015
3	Alemtuzumab (Campath)FDA Link 11/2015 - 12/2002
3	CytokinesIBA 01/2015 - 05/2008
3	Thalidomide (Thalomid)FDA Link 10/2014 - 07/2010
3	Death-Associated Protein KinasesIBA 09/2009 - 11/2003
3	MethyltransferasesIBA 09/2009 - 01/2002
2	COVID-19 VaccinesIBA 01/2024 - 01/2022
2	Immune Checkpoint InhibitorsIBA 12/2023 - 11/2023
2	Complement System Proteins (Complement)IBA 12/2023 - 12/2002
2	Therapeutic UsesIBA 01/2023 - 12/2002
2	IntegrinsIBA 04/2022 - 01/2016
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 04/2022 - 05/2009
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2020
2	Investigational DrugsIBA 01/2021 - 05/2017

Therapy/Procedure

60	Therapeutics 01/2024 - 12/2002
21	Drug Therapy (Chemotherapy) 05/2024 - 01/2003
9	Stem Cell Transplantation 01/2021 - 09/2009
7	Organ Transplantation 12/2022 - 11/2003
6	Transplantation 12/2022 - 03/2014
4	Precision Medicine 10/2021 - 01/2020
3	Radiotherapy 09/2023 - 01/2003
3	Time-to-Treatment 04/2015 - 01/2010
2	Immunotherapy 08/2023 - 02/2018
2	Duration of Therapy 09/2022 - 07/2021
2	Autologous Transplantation 01/2020 - 04/2016
2	Hematopoietic Stem Cell Transplantation 01/2019 - 12/2009
2	Drug Tapering 12/2018 - 01/2017